Skip to search formSkip to main contentSkip to account menu

danoprevir

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
As coronavirus disease 2019 (COVID-19) outbreak, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2… 
Highly Cited
2014
Highly Cited
2014
HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also… 
Highly Cited
2013
Highly Cited
2013
The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a standard viral dynamic model that keeps… 
Highly Cited
2012
Highly Cited
2012
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including… 
Highly Cited
2012
Highly Cited
2012
BACKGROUND & AIMS Although interleukin 28B (interferon, lambda 3) (IL28B) genotype affects the response of patients with chronic… 
2012
2012
ABSTRACT In the INFORM-1 study, 73 patients with chronic hepatitis C virus infection received mericitabine plus danoprevir for up… 
Highly Cited
2011
Highly Cited
2011
Protease inhibitors (PIs) have proven to be effective adjuncts to interferon/ribavirin treatment of hepatitis C virus (HCV… 
2011
2011
ABSTRACT Danoprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that promotes multi-log10 reductions in HCV RNA when… 
Highly Cited
2010
Highly Cited
2010
Background/aim Insulin resistance (IR) is a major predictor of treatment failure in patients with hepatitis C virus (HCV…